Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity

European Neuropsychopharmacology

Volumn 9, Issue 1-2, 1999, Pages 165-170

  Redmond, Anna M ^a   Harkin, Andrew ^a   Kelly, John P ^a   Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Citalopram; Fluoxetine; Locomotor activity; Paroxetine; Phencyclidine; Sertraline

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; PAROXETINE; PHENCYCLIDINE; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; EXCITATORY AMINO ACID ANTAGONISTS; FLUOXETINE; MALE; MOTOR ACTIVITY; PAROXETINE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033010640     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00023-6     Document Type: Article

References (41)

1. Bristow, L.J., Hutson, P.H., Thorn, L., Tricklebank, M.D., 1993. The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol. 108, 1156-1163.
2. Caccia, S., Anelli, M., Codegoni, A.M., Fracasso, C., Garattini, S., 1993. The effects of single or repeated anorectic doses of 5-hydroxy-tryptaminergic uptake inhibitors on indole levels in rat brain. Br. J. Pharmacol. 110, 355-359.
3. Caccia, S., Fracasso, C., Garattini, S., Guiso, G., Sarati, S., 1992. Effects of short and long term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 31, 343-347.
4. Carlsson, M., Svensson, A., 1990. The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494(D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci. 47, 1729-1736.
5. 2 receptors in chronic fluoxetine treated rats. Eur. J. Pharmacol. 322, 123-127.
6. Cotman, C., Monaghan, D.T., 1987. Chemistry and anatomy of excitatory amino acid systems. In: Meltzer, H.Y. (Ed.), Psychopharmacology, The Third Generation of Progress. Raven Press, New York.
7. Freeman, A.S., Bunney, B.S., 1984. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104, 287-293.
8. French, E.D., Mura, A., Wang, T., 1993. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat AlO dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13, 108-116.
9. French, E.D., Pilapil, C., Quirion, R., 1985. Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. Eur. J. Pharmacol. 116, 1-9.
10. Hernandez, L.S., Auerbach, S., Hoebel, B.G., 1988. PCP injected into the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci. 42, 1713-1723.
11. Hiramatsu, M., Cho, A.K., Nabeshima, T., 1989. Comparisons of the behavioural and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166, 359-366.
12. Hoffman, D.C., 1992. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transmission 89, 1-10.
13. Hyttel, J., 1994. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9, 19-26.
14. Kashiwa, A., Nishiokawa, T., Nishijima, K., Umino, A., Takahashi, K., 1995. Dizocilpine (MK-801) elicits a tetrodotoxin-sensitive increase in extracellular release of dopamine in rat medial frontal cortex. Neurochem. Int. 26, 269-279.
15. Koek, W., Colpaert, F.C., 1990. Selective blockage of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioural effects. J. Pharmacol. Exp. Ther. 252, 349-357.
16. 3H]-1-[1-(2-thienyl)cyclohexyl]piperdine. J. Pharmacol. Exp. Ther. 238, 739-748.
17. Leonard, B.E., 1993. The comparative pharmacology of new antidepressants. J. Clin. Psychiatry 54 (Suppl.), 3-15.
18. Lodge, D., Johnson, K.M., 1990. Noncompetitive excitatory amino acid receptor antagonists. TiPS 11, 81-86.
19. 1A receptor antagonist (+) WAY 100,135 on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242, 99-104.
20. Maj, J., Rogoz, Z., Skuza, G., Wedzony, K., 1996. The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a noncompetitive NMDA receptor antagonist. J. Neural Transmission 103, 131-146.
21. Maj, J., Rogoz, Z., Skuza, G., Sowinska, H., 1992. The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacol. 31, 1685-1691.
22. Maj, J., Rogoz, Z., Skuza, G., Sowinska, H., 1992. Effects of MK-801 and antidepressant drugs in the forced swim test in rats. Eur. Neuorpsychopharmacol. 2, 37-41.
23. Maj, J., Rogoz, Z., Skuza, G., 1991. Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J. Neural. Transm. 85, 169-179.
24. Maj, J., 1986. Repeated treatment with antidepressant drugs: responses mediated by brain dopamine receptors. In: Hippius, H., Klerman, G.L, Matussek, N. (Eds.), New Results in Depression Research, Springer-Verlag, Berlin.
25. Mathe, J.M., Nomikos, G.G., Hildebrand, B.E., Hertel, P., Svensson, T.H., 1996. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309, 1-11.
26. Nsimba, S.E.D., Kelly, J.P., Leonard, B.E., 1994. Dose-dependent behavioural effect of phencyclidine (PCP). Med. Sci. Res. 22, 207-209.
27. Ohmori, T., Koyama, T., Nakamura, F., Wang, P., Yamashita, I., 1992. Effect of phencyclidine on spontaneous and N-Methyl-D-Aspartate (NMDA)-induced efflux of dopamine from superfused slices of rat striatum. Neuropharmacol. 31, 461-467.
28. Paul, I.A., Nowak, G., Layers, R.T., Popik, P., Skolnick, P., 1994. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269, 95-102.
29. Pucilowski, O., Overstreet, D.H., 1993. Effect of chronic antidepressant treatment on responses to apomorpine in selectively bred rat strains. Brain Research Bulletin 32, 471-475.
30. 1-like receptors on glutamatergic terminals inhibits N-Methyl-D-Aspartate-induced cyclic GMP production in rat cerebellar slices. J. Pharmacol. Exp. Ther. 257, 1184-1188.
31. 3H]3-PPP binding to σ sites in rat brain. Eur. J. Pharmacol. 165, 335-336.
32. Serra, G., Collu, M., D'Aquila, P., Gessa, G.L., 1992. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol. Toxicol. 71, 72-84.
33. Snell, L.D., Yi, S.J., Johnson, K.M., 1988. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur. J. Pharmcol. 145, 223-226.
34. Srkalovic, G., Selim, M., Rea, M.A., Glass, J.D., 1994. Serotonergic inhibition of extracellular glutamate in the suprachiasmatic nuclear region assessed using in vivo brain microdialysis. Brain Res. 656, 302-308.
35. Steinfels, G.F., Tam, S.W., 1989. Selective σ receptor agonist and antagonist affect dopamine neuronal activity. Eur. J. Pharmacol. 363, 167-170.
36. 3H]BTCP): a new phencyclidine analog selective for the dopamine uptake complex. Eur. J. Pharmacol. 148, 427-436.
37. Walker, J.M., Bowen, W.D., Walker, P.O., Matsumoto, R.R., De Costa, B., Rice, K.C., 1990. Sigma receptors: Biology and Function. Pharmacological Rev. 42, 355-402.
38. Whitton, P., Richards, D., Biggs, C., Fowler, L., 1994. N-methyl-D-aspartate receptors modulate extracellular 5-HT concentrations in rat hippocampus and striatum in vivo. Neuroscience Letters 169, 215-218.
39. 3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J. Neurochem. 50, 274-281.
40. 1 site. J. Neuroscience 15, 731-736.
41. 1 pyramidal cells. Neuropharmacol. 33, 483-491.